A Randomized, Double-Blind (Sponsor-Unblinded), Placebo-Controlled, Single And Multiple Ascending Dose Study To Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Bioavailability and Food Effect (Open-Label) of Sage-319 in Healthy Adult Participants.
Latest Information Update: 19 Sep 2025
At a glance
- Drugs SAGE-319 (Primary)
- Indications Neurological disorders
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Sage Therapeutics
Most Recent Events
- 19 Sep 2025 New trial record